Literature DB >> 18258608

SAG/ROC2/RBX2 E3 ligase promotes UVB-induced skin hyperplasia, but not skin tumors, by simultaneously targeting c-Jun/AP-1 and p27.

Hongbin He1, Qingyang Gu, Min Zheng, Daniel Normolle, Yi Sun.   

Abstract

Sensitive to apoptosis gene (SAG)/regulator of cullins-2/RING box protein 2 is a stress-responsive RING component of Skp-1/Cullins/F-box protein E3 ubiquitin ligase. When overexpressed, SAG inhibits apoptosis induced by reactive oxygen species or hypoxia. Here, we report that SAG overexpression inhibits ultraviolet (UV) B-induced apoptosis in mouse JB6 epidermal cells. Using a transgenic mouse model, in which SAG expression was targeted primarily to epidermis by a K14 promoter, we showed that, at the early stage of UVB skin carcinogenesis (10 weeks post-UVB exposure), c-Jun, p27, p53, c-Fos and cyclin D1 were strongly induced. While having no effect on UVB-induced p53, c-Fos and cyclin D1, SAG-transgenic expression reduced the levels of c-Jun and p27 and inhibited AP-1 activity. The net outcome of SAG-mediated inhibition of c-Jun/AP-1 (pro-tumor promotion) and of p27 (antiproliferation) increased skin hyperplasia, with no apparent effect on apoptosis, as evidenced by increased skin thickness, and increased rate of DNA synthesis, but hardly any apoptosis. Although skin hyperplasia was promoted, SAG-transgenic expression had no significant effect on tumor formation in the later stage of UVB carcinogenesis. Thus, by simultaneously targeting c-Jun and p27, SAG accelerates UVB-induced skin hyperplasia, but not carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258608     DOI: 10.1093/carcin/bgn021

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  25 in total

1.  COP1 and GSK3β cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis.

Authors:  Jing Shao; Yong Teng; Ravi Padia; Sungguan Hong; Hyangsoon Noh; Xiayang Xie; Jeff S Mumm; Zheng Dong; Han-Fei Ding; John Cowell; Jaejik Kim; Jiahuai Han; Shuang Huang
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

2.  Small RING Finger Proteins RBX1 and RBX2 of SCF E3 Ubiquitin Ligases: The Role in Cancer and as Cancer Targets.

Authors:  Dongping Wei; Yi Sun
Journal:  Genes Cancer       Date:  2010-07

Review 3.  SCF E3 ubiquitin ligases as anticancer targets.

Authors:  L Jia; Y Sun
Journal:  Curr Cancer Drug Targets       Date:  2011-03       Impact factor: 3.428

4.  Disruption of Sag/Rbx2/Roc2 induces radiosensitization by increasing ROS levels and blocking NF-kappaB activation in mouse embryonic stem cells.

Authors:  Mingjia Tan; Yueming Zhu; Jordan Kovacev; Yongchao Zhao; Zhen-Qiang Pan; Douglas R Spitz; Yi Sun
Journal:  Free Radic Biol Med       Date:  2010-06-08       Impact factor: 7.376

5.  Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis.

Authors:  Hua Li; Mingjia Tan; Lijun Jia; Dongping Wei; Yongchao Zhao; Guoan Chen; Jie Xu; Lili Zhao; Dafydd Thomas; David G Beer; Yi Sun
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

6.  Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.

Authors:  Dongping Wei; Meredith A Morgan; Yi Sun
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 7.  Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.

Authors:  Chuan-Ming Xie; Wenyi Wei; Yi Sun
Journal:  J Genet Genomics       Date:  2013-02-10       Impact factor: 4.275

Review 8.  Cullin-RING Ligases as attractive anti-cancer targets.

Authors:  Yongchao Zhao; Yi Sun
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 9.  Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase.

Authors:  Yi Sun; Hua Li
Journal:  Protein Cell       Date:  2012-11-08       Impact factor: 14.870

10.  Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target.

Authors:  Lijun Jia; Jie Yang; Xinbao Hao; Min Zheng; Hongbin He; Xiufang Xiong; Liang Xu; Yi Sun
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.